A Phase I, Randomised, Open Label, Single Center, Single Oral Dose, Three Treatment, Three Period, Three Sequence, Change-over Bioequivalence Study of Paracetamol Orodispersible Tablet 500 mg (Haleon) to assess Bioequivalence with Alvedon 500 mg Film-Coated Tablet (Haleon, Sweden) and Panadol 500 mg Film-Coated Tablet (Haleon, Australia) in Healthy Adult Subjects Under Fasting Conditions
300141
Phase 1 other active
Quick answer
A Phase I, Randomised, Open Label, Single Center, Single Oral Dose, Three Treatment, Three Period, Three Sequence, Change-over Bioequivalence Study of Paracetamol Orodispersible Tablet 500 mg (Haleon) to assess Bioequivalence with Alvedon 500 mg Film-Coated Tablet (Haleon, Sweden) and Panadol 500 mg Film-Coated Tablet (Haleon, Australia) in Healthy Adult Subjects Under Fasting Conditions for Healthy volunteers, therapeutic indication not studied is a Phase 1 program (other) at Haleon Ireland Dungarvan Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Haleon Ireland Dungarvan Limited
- Indication
- Healthy volunteers, therapeutic indication not studied
- Phase
- Phase 1
- Modality
- other
- Status
- active